Poxel - Pharmaceutical Company set-up to find innovative solutions for metabolic diseases management with a primary focus on type 2 diabetes

Board of Directors

Thierry Hercend

MD, PhD, Venture Partner at EdRIP, Chairman of the Board


Raphaël Wisniewski

Investment Director at EdRIP


Olivier Martinez

PhD, MBA, Investment Manager, Life Science team, CDC Entreprises


Bruno Montanari

Pharm D, HEC Masters, Investment Manager at Omnes Capital (formerly Credit Agricole Private Equity)

Thomas Kuhn

Pharm D, MBA, CEO of Poxel

Khoso Baluch

SVP & President Europe Region at UCB, Independent administrator

Thierry Hercend

Thierry Hercend

Thierry Hercend has over 30 years' experience in both academia and the pharmaceutical industry, in various therapeutic areas including oncology and inflammatory diseases. Since 2006, he has been Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). From 2002 to 2005, Dr Hercend was Vice President in charge of the oncology therapeutic area at Aventis. From 1998 to 2002, he was Vice President of Research,

Europe at Vertex Pharmaceuticals. Previously, Dr Hercend was Head of Research and Development for the Laboratory of Plasma Fractionation and Biotechnology (LFB) and held various executive R&D positions with Roussel-Uclaf. Prior to joining the pharmaceutical industry, Dr Hercend was Head of the Hemato-Immunology Unit of the Gustave Roussy Cancer Institute, Villejuif, France; Director of Inserm Unit U333 dedicated to tumor immunology; and Professor of Immunology at the Medical Faculty of Paris XI University.

He has authored more than 120 publications in oncology, autoimmune diseases and transplantation.

Raphaël Wisniewski

Raphaël Wisniewski

Raphaël Wisniewski is investment director at Edmond de Rothschild Investment Partners (EdRIP) in the life sciences venture group. He sits on the board of several European life sciences companies on behalf of EdRIP. Prior to joining EdRIP in 2001, Mr. Wisniewski spent several years in London working for the hospital group General Healthcare Group and in the corporate finance practices of Salomon Smith Barney and Goldman Sachs.

 

Olivier Martinez

Olivier Martinez

Olivier Martinez joined Bioam Gestion in 2000 as an Associate and became Investment Manager and member of the executive board in 2004. Following the integration of Bioam Gestion into CDC Entreprises in July 2010, he is now in charge of managing investments of the InnoBio and Bioam funds. He currently serves on the boards of Cytheris, Adocia, Fab Pharma and Genticel. Prior to joining Bioam Gestion, Dr. Martinez spent two years working

on healthcare projects in the Life Science Group of Gemini Consulting. From 1992 to 1997, he pursued his doctoral studies in cell biology at the Pasteur and Curie Institutes in Paris, followed by management training. He is an alumnus of the Ecole Normale Supérieure and holds a PhD in cell biology from the University of Paris XI and a diploma from the Collège des Ingénieurs.

Bruno Montanari

Bruno Montanari

Bruno Montanari joined CAPE in January 2010 as an Investment Manager, and he currently serves on the boards of Biospace Med and Xention. From 2004 he was with Atlas Venture, where as a Principal he was responsible for several medical device and drug development portfolio companies. From 2002 to 2004 he was Life Sciences Investment Director for the Paris office of CDP Capital Technology Ventures. Dr. Montanari

began his career in 1999 in London with Deutsche Bank and later Merrill Lynch as a member of the Investment Banking teams covering the European pharmaceutical and biotech sectors. He holds a PharmD (Paris V) and a Masters from HEC (Paris).

Thomas Kuhn

Thomas Kuhn

Thomas Kuhn joined Merck KGaA in 2000, where he held various positions in clinical development, largely in the area of diabetes. Between 2004 and 2007 he directed global R&D projects, with two products in Phase II clinical trials, and life cycle management projects, specifically for Glucophage®, the current reference in diabetes treatment. After the integration of Serono in 2007, Thomas was involved in refining Merck Serono's

strategy. With the decision to divest from diabetes as an integrated therapeutic area, Thomas drove the project to relocate the diabetes assets, leading to the establishment of Poxel. Thomas received a pharmacy degree from the University of Lyon I (France) and an MBA from Ashridge University (UK).

Khoso Baluch

Khoso Baluch

Khoso Baluch is senior vice president & President European Region at UCB, the global biopharmaceutical company. Prior to joining UCB, Khoso worked for Eli Lilly & Co for 24 years, holding international positions spanning Europe, the Middle East and the United States in General Management, Business Development, Market Access and Product leadership. Khoso was appointed Vice President of U.S. Diabetes and Family Health Business unit during his tenure

at Lilly. He served as a Board Member of the Juvenile Diabetes Research Foundation, Indiana Chapter, and was Chair of the nomination committee. He also served at the American Diabetes Association National Industry Advisory Board. Khoso is also a member of the World Federation of Advertisers (WFA) Executive Committee.

Sitemap | Legal
© Poxel SA